ReViral Ltd., a clinical-stage biopharmaceutical company, has raised $44 million in Series C financing. CR-CP Life Science Fund led the round with participation from other investors that included Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors and Perceptive Advisors.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: